PLIVA Completes Divestment of VoSpire
PLIVA d.d. announced that it has completed the divestment of VoSpire of its US branded subsidiary Odyssey Pharmaceuticals Inc., to DAVA Pharmaceuticals Inc., (DAVA) a privately held specialty pharmaceutical company. PLIVA received a total payment of USD 32m for the transaction upon closing as well as the right to additional potential payments of up to USD 35.5m for the achievement of certain milestones. The closing of the transaction will positively impact PLIVA Group results with an exceptional book gain of about USD 25m in the fourth quarter 2005.
Organizations
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.